Table 1.
Patient characteristicsa
| Characteristicsb | Total (N=1,025) | SIS=0 (N=470) | SIS=1 (N=413) | P1-value | SIS=2 (N=142) | P2-value |
|---|---|---|---|---|---|---|
| Median age (years) | 62 (57–67) | 61 (55–66) | 63 (56–69) | 0.004 | 66 (60–71) | <0.001 |
| Gender | ||||||
| Male | 530 (51.7%) | 170 (36.2%) | 256 (62.0%) | <0.001 | 104 (73.2%) | <0.001 |
| Female | 495 (48.3%) | 300 (63.8%) | 157 (38.0%) | 38 (26.8%) | ||
| Median body mass index (kg/m2) | 23.3 (21.1–25.2) | 23.2 (21.1–25.1) | 23.4 (21.2–25.4) | 0.090 | 22.9 (20.5–26.3) | 0.92 |
| Median FEV1% | 83.8 (73.8–92.7) | 87.3 (80.3–96.5) | 80.8 (70.3–89.8) | <0.001 | 74.7 (64.9–86.8) | <0.001 |
| Median FEV1/FVC (%) | 79.0 (74.2–83.5) | 81.3 (76.4–84.7) | 77.9 (73.0–82.9) | <0.001 | 74.9 (66.8–79.4) | <0.001 |
| Median neutrophil-to-lymphocyte ratio | 1.9 (1.4–2.5) | 1.5 (1.2–1.9) | 2.3 (1.8–3.1) | <0.001 | 2.4 (1.7–3.1) | <0.001 |
| Median platelet-to-lymphocyte ratio | 91.5 (72.4–120.0) | 82.7 (64.9–102.6) | 101.6 (78.0–133.8) | <0.001 | 105.7 (81.6–162.7) | <0.001 |
| Median hemoglobin (g/dL) | 13.6 (12.8–14.6) | 13.5 (12.9–14.5) | 13.8 (12.9–14.8) | 0.11 | 13.2 (12.1–14.2) | <0.001 |
| Smoking history | 380 (37.1%) | 99 (21.1%) | 198 (47.9%) | <0.001 | 83 (58.5%) | <0.001 |
| Respiratory comorbidity | 400 (39.0%) | 146 (31.1%) | 183 (44.3%) | <0.001 | 71 (50.0%) | <0.001 |
| Cardio-cerebrovascular comorbidity | 382 (37.3%) | 134 (28.5%) | 181 (43.8%) | <0.001 | 67 (47.2%) | <0.001 |
| Diabetes mellitus | 112 (10.9%) | 36 (7.7%) | 59 (14.3%) | 0.002 | 17 (12.0%) | 0.11 |
| Renal insufficiency | 89 (8.7%) | 35 (7.4%) | 38 (9.2%) | 0.35 | 16 (11.3%) | 0.15 |
| Steroid use | 31 (3.0%) | 11 (2.3%) | 14 (3.4%) | 0.35 | 6 (4.2%) | 0.23 |
| Tumor location | ||||||
| Right upper lobe | 334 (32.6%) | 164 (34.9%) | 136 (32.9%) | 0.44 | 34 (23.9%) | 0.25 |
| Left upper lobe | 261 (25.5%) | 127 (27.0%) | 99 (24.0%) | 35 (24.6%) | ||
| Right lower lobe | 193 (18.8%) | 81 (17.2%) | 78 (18.9%) | 34 (23.9%) | ||
| Left lower lobe | 149 (14.5%) | 56 (11.9%) | 65 (15.7%) | 28 (19.7%) | ||
| Right middle lobe | 88 (8.6%) | 42 (8.9%) | 35 (8.5%) | 11 (7.7%) | ||
| Dense pleural adhesion | ||||||
| Absent | 935 (91.2%) | 429 (91.3%) | 374 (90.6%) | 0.71 | 132 (93.0%) | 0.53 |
| Present | 90 (8.8%) | 41 (8.7%) | 39 (9.4%) | 10 (7.0%) | ||
| Pulmonary fissure completeness | ||||||
| Complete | 596 (58.1%) | 285 (60.6%) | 242 (58.6%) | 0.54 | 69 (48.6%) | 0.011 |
| Incomplete | 429 (41.9%) | 185 (39.4%) | 171 (41.4%) | 73 (51.4%) | ||
| Median estimated intraoperative blood loss (mL) | 50 (20–50) | 30 (20–50) | 50 (20–60) | 0.053 | 50 (30–60) | <0.001 |
| Median Operation time (mins) | 100 (80–130) | 100 (75–130) | 105 (80–130) | 0.016 | 120 (90–150) | <0.001 |
| Histological subtypes | ||||||
| Adenocarcinoma | 822 (80.2%) | 386 (82.1%) | 339 (82.1%) | 0.99 | 97 (68.3%) | <0.001 |
| Non-adenocarcinoma | 203 (19.8%) | 84 (17.9%) | 74 (17.9%) | 45 (31.7%) | ||
| Tumor invasion (T-stage) | ||||||
| T1 | 627 (61.2%) | 322 (68.5%) | 237 (57.4%) | 0.001 | 68 (47.9%) | <0.001 |
| T2-3 | 398 (38.8%) | 148 (31.5%) | 176 (42.6%) | 74 (52.1%) | ||
| Lymph node metastasis (N-stage) | ||||||
| N0 | 966 (94.2%) | 453 (96.4%) | 389 (94.2%) | 0.12 | 124 (87.3%) | 0.001 |
| N1-2 | 59 (5.8%) | 17 (3.6%) | 24 (5.8%) | 18 (12.7%) | ||
Notes: aP1-value indicates demographic differences between patients with SIS=1 and with SIS=0. P2-value indicates demographic differences between patients with SIS=2 and with SIS=0. bThe continuous data were presented as medians with 25th–75th percentile-intervals.
Abbreviations: FEV1/FVC, FEV1 to FVC ratio; SIS, Systemic inflammation score.